506 related articles for article (PubMed ID: 26558806)
21. Mutation Update for UBE3A variants in Angelman syndrome.
Sadikovic B; Fernandes P; Zhang VW; Ward PA; Miloslavskaya I; Rhead W; Rosenbaum R; Gin R; Roa B; Fang P
Hum Mutat; 2014 Dec; 35(12):1407-17. PubMed ID: 25212744
[TBL] [Abstract][Full Text] [Related]
22. The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology.
Dindot SV; Antalffy BA; Bhattacharjee MB; Beaudet AL
Hum Mol Genet; 2008 Jan; 17(1):111-8. PubMed ID: 17940072
[TBL] [Abstract][Full Text] [Related]
23. Truncation of Ube3a-ATS unsilences paternal Ube3a and ameliorates behavioral defects in the Angelman syndrome mouse model.
Meng L; Person RE; Huang W; Zhu PJ; Costa-Mattioli M; Beaudet AL
PLoS Genet; 2013; 9(12):e1004039. PubMed ID: 24385930
[TBL] [Abstract][Full Text] [Related]
24. The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc.
Greer PL; Hanayama R; Bloodgood BL; Mardinly AR; Lipton DM; Flavell SW; Kim TK; Griffith EC; Waldon Z; Maehr R; Ploegh HL; Chowdhury S; Worley PF; Steen J; Greenberg ME
Cell; 2010 Mar; 140(5):704-16. PubMed ID: 20211139
[TBL] [Abstract][Full Text] [Related]
25. Genomic imprinting of experience-dependent cortical plasticity by the ubiquitin ligase gene Ube3a.
Sato M; Stryker MP
Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5611-6. PubMed ID: 20212164
[TBL] [Abstract][Full Text] [Related]
26. Impaired hippocampal plasticity and altered neurogenesis in adult Ube3a maternal deficient mouse model for Angelman syndrome.
Mardirossian S; Rampon C; Salvert D; Fort P; Sarda N
Exp Neurol; 2009 Dec; 220(2):341-8. PubMed ID: 19782683
[TBL] [Abstract][Full Text] [Related]
27. Generation of a Novel Rat Model of Angelman Syndrome with a Complete Ube3a Gene Deletion.
Dodge A; Peters MM; Greene HE; Dietrick C; Botelho R; Chung D; Willman J; Nenninger AW; Ciarlone S; Kamath SG; Houdek P; Sumová A; Anderson AE; Dindot SV; Berg EL; O'Geen H; Segal DJ; Silverman JL; Weeber EJ; Nash KR
Autism Res; 2020 Mar; 13(3):397-409. PubMed ID: 31961493
[TBL] [Abstract][Full Text] [Related]
28. A placebo-controlled trial of folic acid and betaine in identical twins with Angelman syndrome.
Han J; Bichell TJ; Golden S; Anselm I; Waisbren S; Bacino CA; Peters SU; Bird LM; Kimonis V
Orphanet J Rare Dis; 2019 Oct; 14(1):232. PubMed ID: 31640736
[TBL] [Abstract][Full Text] [Related]
29. Quantitative proteomics reveals neuronal ubiquitination of Rngo/Ddi1 and several proteasomal subunits by Ube3a, accounting for the complexity of Angelman syndrome.
Ramirez J; Lectez B; Osinalde N; Sivá M; Elu N; Aloria K; Procházková M; Perez C; Martínez-Hernández J; Barrio R; Šašková KG; Arizmendi JM; Mayor U
Hum Mol Genet; 2018 Jun; 27(11):1955-1971. PubMed ID: 29788202
[TBL] [Abstract][Full Text] [Related]
30. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons.
Huang HS; Allen JA; Mabb AM; King IF; Miriyala J; Taylor-Blake B; Sciaky N; Dutton JW; Lee HM; Chen X; Jin J; Bridges AS; Zylka MJ; Roth BL; Philpot BD
Nature; 2011 Dec; 481(7380):185-9. PubMed ID: 22190039
[TBL] [Abstract][Full Text] [Related]
31. Activity-dependent changes in MAPK activation in the Angelman Syndrome mouse model.
Filonova I; Trotter JH; Banko JL; Weeber EJ
Learn Mem; 2014 Jan; 21(2):98-104. PubMed ID: 24434871
[TBL] [Abstract][Full Text] [Related]
32. Angelman syndrome scientific symposium on the structure and function of UBE3A/E6AP.
Williams C
J Child Neurol; 2009 Jul; 24(7):904-8. PubMed ID: 19617463
[TBL] [Abstract][Full Text] [Related]
33. Enhanced Nociception in Angelman Syndrome Model Mice.
McCoy ES; Taylor-Blake B; Aita M; Simon JM; Philpot BD; Zylka MJ
J Neurosci; 2017 Oct; 37(42):10230-10239. PubMed ID: 28931574
[TBL] [Abstract][Full Text] [Related]
34. Decreased tonic inhibition in cerebellar granule cells causes motor dysfunction in a mouse model of Angelman syndrome.
Egawa K; Kitagawa K; Inoue K; Takayama M; Takayama C; Saitoh S; Kishino T; Kitagawa M; Fukuda A
Sci Transl Med; 2012 Dec; 4(163):163ra157. PubMed ID: 23220633
[TBL] [Abstract][Full Text] [Related]
35. Angelman syndrome-derived neurons display late onset of paternal UBE3A silencing.
Stanurova J; Neureiter A; Hiber M; de Oliveira Kessler H; Stolp K; Goetzke R; Klein D; Bankfalvi A; Klump H; Steenpass L
Sci Rep; 2016 Aug; 6():30792. PubMed ID: 27484051
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic regulation of UBE3A and roles in human neurodevelopmental disorders.
LaSalle JM; Reiter LT; Chamberlain SJ
Epigenomics; 2015 Oct; 7(7):1213-28. PubMed ID: 26585570
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological therapies for Angelman syndrome.
Tan WH; Bird LM
Wien Med Wochenschr; 2017 Jun; 167(9-10):205-218. PubMed ID: 26758979
[TBL] [Abstract][Full Text] [Related]
38. A high-fidelity RNA-targeting Cas13 restores paternal Ube3a expression and improves motor functions in Angelman syndrome mice.
Li J; Shen Z; Liu Y; Yan Z; Liu Y; Lin X; Tang J; Lv R; Geng G; Xiong ZQ; Zhou C; Yang H
Mol Ther; 2023 Jul; 31(7):2286-2295. PubMed ID: 36805082
[TBL] [Abstract][Full Text] [Related]
39. CRISPR/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice.
Schmid RS; Deng X; Panikker P; Msackyi M; Breton C; Wilson JM
J Clin Invest; 2021 Mar; 131(5):. PubMed ID: 33411694
[TBL] [Abstract][Full Text] [Related]
40. Neurobehavioral and electroencephalographic abnormalities in Ube3a maternal-deficient mice.
Miura K; Kishino T; Li E; Webber H; Dikkes P; Holmes GL; Wagstaff J
Neurobiol Dis; 2002 Mar; 9(2):149-59. PubMed ID: 11895368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
